Home › NDC Lookup › RxCUI directory › RxCUI 1790175

Cabozantinib 60 MG Oral Tablet [Cabometyx] — RxCUI 1790175

RxNorm drug concept · Semantic branded drug
RxCUI 1790175 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 13 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1790175
Official nameCabozantinib 60 MG Oral Tablet [Cabometyx]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asCabometyx 60 MG Oral Tablet; Cabometyx 60 MG (as cabozantinib (S)-malate 76 MG) Oral Tablet
FDA products mapped3
Package NDCs mapped13
Reported Medicaid activity (SDUD)3,816 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cabozantinib (thyroid cancer): what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Cabozantinib is designed for a type of thyroid cancer called differentiated thyroid cancer (DTC) that has continued to grow even after other targeted treatments, and when radioacti...
  • Why is my doctor prescribing this specific medication for my thyroid cancer?
  • Yes, this is actually really important. You need to take it on a completely empty stomach — at least 1 hour before eating anything or at least 2 hours after your last meal. Food, e...
  • Does it matter when I take it — like, can I take it with breakfast?
📖 Read our full Cabozantinib (thyroid cancer) guide →

🕸️ Concept Web — How Cabozantinib 60 MG Oral Tablet [Cabometyx] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cabozantinib 60 MG Oral Tablet [Cabometyx] RxCUI 1790175

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cabozantinib 1363268
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Cabometyx 1790162
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cabozantinib Oral Tablet 1790160
    • Cabozantinib Oral Product 1363270
    • Cabozantinib Pill 1363271
    • Cabozantinib Oral Tablet [Cabometyx] 1790164
    • Cabometyx Oral Product 1790165
    • Cabometyx Pill 1790166
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cabozantinib 60 MG Oral Tablet SCD · 1790173
  • Cabozantinib 60 MG SCDC · 1790172
  • Cabozantinib Oral Tablet SCDF · 1790160
  • Cabozantinib Oral Product SCDG · 1363270
  • Cabozantinib Pill SCDG · 1363271

Brand-Name Concepts

  • Cabozantinib 60 MG [Cabometyx] SBDC · 1790174
  • Cabozantinib Oral Tablet [Cabometyx] SBDF · 1790164
  • Cabometyx Oral Product SBDG · 1790165
  • Cabometyx Pill SBDG · 1790166
  • Cabometyx BN · 1790162

📦 FDA Products & Package NDCs

3 products · 13 package NDCs
13 package NDCs map to RxCUI 1790175 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42388-0023-26 30 TABLET in 1 BOTTLE (42388-023-26) CABOMETYX Exelixis, Inc. 2016-04-25
42388-0023-36 30 TABLET in 1 BOTTLE (42388-023-36) CABOMETYX Exelixis, Inc. 2017-11-16
42388-0023-37 15 TABLET in 1 BOTTLE (42388-023-37) CABOMETYX Exelixis, Inc. 2018-10-03
42388-0023-46 1 BOTTLE in 1 CARTON (42388-023-46) / 30 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
42388-0023-57 1 BOTTLE in 1 CARTON (42388-023-57) / 15 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
42388-0024-26 30 TABLET in 1 BOTTLE (42388-024-26) CABOMETYX Exelixis, Inc. 2016-04-25
42388-0024-37 15 TABLET in 1 BOTTLE (42388-024-37) CABOMETYX Exelixis, Inc. 2019-02-27
42388-0024-46 1 BOTTLE in 1 CARTON (42388-024-46) / 30 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
42388-0024-57 1 BOTTLE in 1 CARTON (42388-024-57) / 15 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
42388-0025-26 30 TABLET in 1 BOTTLE (42388-025-26) CABOMETYX Exelixis, Inc. 2016-04-25
42388-0025-37 15 TABLET in 1 BOTTLE (42388-025-37) CABOMETYX Exelixis, Inc. 2019-02-27
42388-0025-46 1 BOTTLE in 1 CARTON (42388-025-46) / 30 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
42388-0025-57 1 BOTTLE in 1 CARTON (42388-025-57) / 15 TABLET in 1 BOTTLE CABOMETYX Exelixis, Inc. 2023-01-09
Observed labelers: Exelixis, Inc. (13) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.